Nilotinib-Associated Destructive Thyroiditis
Joint Authors
Bakerywala, Suhalia
Schwarcz, Monica D.
Goldberg, Michael D.
Valiquette, Guy
Weiss, Irene A.
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-05-07
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia.
They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia.
Tyrosine kinases are enzymes expressed in multiple tissues and are involved in several signaling pathways influencing cellular growth.
Below we describe a patient who developed an unusual complication of tyrosine kinase inhibitor therapy: thyrotoxicosis due to destructive thyroiditis.
We review the pathophysiology of tyrosine kinase inhibitor-induced thyroid dysfunction particularly with regard to new second-generation tyrosine kinase inhibitors.
American Psychological Association (APA)
Bakerywala, Suhalia& Schwarcz, Monica D.& Goldberg, Michael D.& Valiquette, Guy& Weiss, Irene A.. 2015. Nilotinib-Associated Destructive Thyroiditis. Case Reports in Endocrinology،Vol. 2015, no. 2015, pp.1-3.
https://search.emarefa.net/detail/BIM-1058418
Modern Language Association (MLA)
Bakerywala, Suhalia…[et al.]. Nilotinib-Associated Destructive Thyroiditis. Case Reports in Endocrinology No. 2015 (2015), pp.1-3.
https://search.emarefa.net/detail/BIM-1058418
American Medical Association (AMA)
Bakerywala, Suhalia& Schwarcz, Monica D.& Goldberg, Michael D.& Valiquette, Guy& Weiss, Irene A.. Nilotinib-Associated Destructive Thyroiditis. Case Reports in Endocrinology. 2015. Vol. 2015, no. 2015, pp.1-3.
https://search.emarefa.net/detail/BIM-1058418
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1058418